S&P 500   3,771.43 (-0.51%)
DOW   30,203.93 (-0.37%)
QQQ   280.95 (-0.42%)
AAPL   145.72 (-0.26%)
MSFT   248.32 (-0.23%)
META   137.85 (-1.73%)
GOOGL   100.77 (-0.86%)
AMZN   120.40 (-0.57%)
TSLA   238.86 (-4.24%)
NVDA   130.80 (-0.66%)
NIO   15.91 (-4.90%)
BABA   84.20 (+0.11%)
AMD   67.53 (-0.54%)
T   15.92 (-1.06%)
MU   54.54 (+1.07%)
CGC   3.02 (-3.82%)
F   12.43 (+0.57%)
GE   67.50 (-0.06%)
DIS   100.05 (-1.37%)
AMC   7.38 (-5.75%)
PYPL   93.79 (+1.08%)
PFE   44.04 (-0.94%)
NFLX   233.56 (-2.98%)
S&P 500   3,771.43 (-0.51%)
DOW   30,203.93 (-0.37%)
QQQ   280.95 (-0.42%)
AAPL   145.72 (-0.26%)
MSFT   248.32 (-0.23%)
META   137.85 (-1.73%)
GOOGL   100.77 (-0.86%)
AMZN   120.40 (-0.57%)
TSLA   238.86 (-4.24%)
NVDA   130.80 (-0.66%)
NIO   15.91 (-4.90%)
BABA   84.20 (+0.11%)
AMD   67.53 (-0.54%)
T   15.92 (-1.06%)
MU   54.54 (+1.07%)
CGC   3.02 (-3.82%)
F   12.43 (+0.57%)
GE   67.50 (-0.06%)
DIS   100.05 (-1.37%)
AMC   7.38 (-5.75%)
PYPL   93.79 (+1.08%)
PFE   44.04 (-0.94%)
NFLX   233.56 (-2.98%)
S&P 500   3,771.43 (-0.51%)
DOW   30,203.93 (-0.37%)
QQQ   280.95 (-0.42%)
AAPL   145.72 (-0.26%)
MSFT   248.32 (-0.23%)
META   137.85 (-1.73%)
GOOGL   100.77 (-0.86%)
AMZN   120.40 (-0.57%)
TSLA   238.86 (-4.24%)
NVDA   130.80 (-0.66%)
NIO   15.91 (-4.90%)
BABA   84.20 (+0.11%)
AMD   67.53 (-0.54%)
T   15.92 (-1.06%)
MU   54.54 (+1.07%)
CGC   3.02 (-3.82%)
F   12.43 (+0.57%)
GE   67.50 (-0.06%)
DIS   100.05 (-1.37%)
AMC   7.38 (-5.75%)
PYPL   93.79 (+1.08%)
PFE   44.04 (-0.94%)
NFLX   233.56 (-2.98%)
S&P 500   3,771.43 (-0.51%)
DOW   30,203.93 (-0.37%)
QQQ   280.95 (-0.42%)
AAPL   145.72 (-0.26%)
MSFT   248.32 (-0.23%)
META   137.85 (-1.73%)
GOOGL   100.77 (-0.86%)
AMZN   120.40 (-0.57%)
TSLA   238.86 (-4.24%)
NVDA   130.80 (-0.66%)
NIO   15.91 (-4.90%)
BABA   84.20 (+0.11%)
AMD   67.53 (-0.54%)
T   15.92 (-1.06%)
MU   54.54 (+1.07%)
CGC   3.02 (-3.82%)
F   12.43 (+0.57%)
GE   67.50 (-0.06%)
DIS   100.05 (-1.37%)
AMC   7.38 (-5.75%)
PYPL   93.79 (+1.08%)
PFE   44.04 (-0.94%)
NFLX   233.56 (-2.98%)
NASDAQ:SPRO

Spero Therapeutics - SPRO News Today

$2.10
+0.10 (+5.00%)
(As of 10/5/2022 01:45 PM ET)
Add
Compare
Today's Range
$2.02
$2.13
50-Day Range
$0.68
$2.20
52-Week Range
$0.68
$18.84
Volume
38,655 shs
Average Volume
23.12 million shs
Market Capitalization
$73.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.33
Get Spero Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SPRO and its competitors with MarketBeat's FREE daily newsletter.



SPRO Media Mentions By Week

SPRO Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

SPRO
News Sentiment

0.73

0.79

Average
Medical
News Sentiment

SPRO News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

SPRO Articles
This Week

3

2

SPRO Articles
Average Week

SourceHeadline
seekingalpha.com logoSpero Therapeutics: The GlaxoSmithKline-Deal Changes Everything And Protects Shareholder Value
seekingalpha.com - October 3 at 8:34 AM
finance.yahoo.com logoSpero Therapeutics to Host Virtual R&D Event on Non-Tuberculous Mycobacterial Pulmonary Disease and the SPR720 Program
finance.yahoo.com - October 3 at 8:34 AM
MarketBeat logoAquilo Capital Management, Llc Sells 1,901,796 Shares of Spero Therapeutics, Inc. (NASDAQ:SPRO) Stock
americanbankingnews.com - September 29 at 4:06 AM
MarketBeat logoHC Wainwright Lowers Spero Therapeutics (NASDAQ:SPRO) Price Target to $6.00
americanbankingnews.com - September 28 at 2:12 AM
MarketBeat logoSpero Therapeutics (NASDAQ:SPRO) Price Target Lowered to $6.00 at HC Wainwright
americanbankingnews.com - September 26 at 7:36 AM
finance.yahoo.com logoThis Infection-Fighting Biotech Is Recovering Nicely
finance.yahoo.com - September 25 at 8:03 AM
MarketBeat logoEvercore ISI Upgrades Spero Therapeutics (NASDAQ:SPRO) to "Outperform"
americanbankingnews.com - September 25 at 3:48 AM
finance.yahoo.com logoSpero (SPRO) Skyrockets 168% on Licensing Deal With GSK
finance.yahoo.com - September 23 at 2:41 PM
benzinga.com logoSpero Therapeutics To Rally Around 240%? Plus This Analyst Slashes PT On Salesforce
benzinga.com - September 23 at 10:42 AM
msn.com logoGSK eyes Spero's experimental urinary tract infection drug, takes stake
msn.com - September 22 at 12:36 PM
markets.businessinsider.com logoGSK To Receive Licence From Spero To Develop, Commercialise Tebipenem Pivoxil HBr
markets.businessinsider.com - September 22 at 7:36 AM
msn.com logoGSK takes stake in Spero in deal for experimental UTI treatment
msn.com - September 22 at 7:36 AM
seekingalpha.com logoSpero stock soars 79% as GSK to pick stake under license deal for UTI antibiotic
seekingalpha.com - September 22 at 7:36 AM
marketwatch.com logoSpero Therapeutics Shares Take Flight Premarket on GSK Pact >SPRO
marketwatch.com - September 22 at 7:36 AM
finance.yahoo.com logoGSK and Spero Therapeutics Announce Exclusive License Agreement for Late-Stage Antibiotic Asset, Tebipenem HBr
finance.yahoo.com - September 22 at 2:35 AM
finance.yahoo.com logoSpero Therapeutics Announces Appointment of Kamal Hamed, MD, MPH, MBA, as Chief Medical Officer
finance.yahoo.com - September 15 at 8:11 PM
nasdaq.com logoSpero Therapeutics Rises
nasdaq.com - September 7 at 5:48 PM
finance.yahoo.com logoSpero Therapeutics to Present at Upcoming Investor Conference
finance.yahoo.com - September 7 at 12:48 PM
finance.yahoo.com logoSpero (SPRO) Up Following Positive FDA Update for UTI Drug
finance.yahoo.com - September 7 at 12:48 PM
msn.com logoAnalyzing Spero Therapeutics's Short Interest
msn.com - September 6 at 4:46 PM
finance.yahoo.com logoSpero Therapeutics Shares Jump After Upbeat FDA Feedback For Tebipenem HBr Program
finance.yahoo.com - September 6 at 4:46 PM
nasdaq.com logoSpero Therapeutics Discusses Resubmission Of NDA For Tebipenem HBr After Discussion With FDA
nasdaq.com - September 6 at 11:45 AM
finance.yahoo.com logoSpero Therapeutics Provides Tebipenem HBr Program Update Following Type A Meeting with the U.S. Food and Drug Administration
finance.yahoo.com - September 6 at 11:45 AM
finance.yahoo.com logoCan Spero Therapeutics (NASDAQ:SPRO) Afford To Invest In Growth?
finance.yahoo.com - September 5 at 10:25 AM
finance.yahoo.com logoSpero Therapeutics, Inc. (SPRO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
finance.yahoo.com - August 25 at 11:50 AM
seekingalpha.com logoSpero Therapeutics, Inc. (SPRO) CEO Ankit Mahadevia on Q2 2022 Results - Earnings Call Transcript
seekingalpha.com - August 11 at 8:30 PM
nz.finance.yahoo.com logoSpero Therapeutics Announces Second Quarter 2022 Operating Results and Provides Business Update
nz.finance.yahoo.com - August 10 at 9:04 PM
markets.businessinsider.com logoSpero Therapeutics is about to announce earnings — here's what Wall Street expects
markets.businessinsider.com - August 10 at 11:03 AM
finance.yahoo.com logoSpero Therapeutics to Provide Business Update and Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022
finance.yahoo.com - August 9 at 11:50 AM
benzinga.com logoFINAL DEADLINE ALERT: The Schall Law Firm Encourages Investors in Spero Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
benzinga.com - July 25 at 2:59 PM
apnews.com logoDEADLINE ALERT for SPRO, LMPX, MF, and YQ: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders
apnews.com - July 25 at 2:59 PM
benzinga.com logoThe Gross Law Firm Announces Class Actions on Behalf of Shareholders of SPRO, OM and MF
benzinga.com - July 25 at 2:59 PM
morningstar.com logoPomerantz Law Firm Announces the Filing of a Class Action Against Spero Therapeutics, Inc. and Certain Officers - SPRO
morningstar.com - July 23 at 9:06 AM
benzinga.com logoThe Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of CDNA, SPRO and TGTX
benzinga.com - July 22 at 1:00 PM
benzinga.com logoCLASS ACTION UPDATE for SPRO, WM and OM: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
benzinga.com - July 21 at 11:02 AM
finance.yahoo.com logoThe Women Who Shaped Short-Term Rental History
finance.yahoo.com - July 6 at 4:07 AM
investing.com logoSpero Therapeutics Plummets 15% on FDA's CRL for Tebipenem HBr New Drug Application
investing.com - June 27 at 5:55 PM
nasdaq.com logoU.S. FDA declines to approve Spero's urinary tract infection drug
nasdaq.com - June 27 at 5:55 PM
seekingalpha.com logoFDA rejects Spero's application seeking approval of its urinary tract infection tablets
seekingalpha.com - June 27 at 5:55 PM
finance.yahoo.com logoSpero Therapeutics Receives Complete Response Letter from U.S. Food and Drug Administration for Tebipenem HBr New Drug Application
finance.yahoo.com - June 27 at 5:55 PM
finance.yahoo.com logoUPDATE 1-U.S. FDA declines to approve Spero's urinary tract infection drug
finance.yahoo.com - June 27 at 5:55 PM
apnews.com logoINVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Spero Therapeutics, Inc. with Losses of $100,000 to Contact the Firm
apnews.com - June 17 at 5:42 PM
apnews.com logoSpero Therapeutics, Inc. Investor News: Robbins LLP is Investigating Spero Therapeutics, Inc. (SPRO) on Behalf of Shareholders
apnews.com - June 16 at 11:52 AM
apnews.com logoGlancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Spero Therapeutics, Inc. (SPRO)
apnews.com - June 10 at 6:31 PM
morningstar.com logoSPRO LAWSUIT ALERT: Levi & Korsinsky Notifies Spero Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline
morningstar.com - June 10 at 9:19 AM
benzinga.com logoSPRO ALERT: The Klein Law Firm Announces a Lead...
benzinga.com - June 8 at 8:05 AM
tmcnet.com logoThe Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Spero Therapeutics, Inc. (SPRO) Investors
tmcnet.com - June 6 at 3:58 PM
benzinga.com logoCLASS ACTION UPDATE for AMZN, SPRO and IONQ: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
benzinga.com - June 3 at 3:23 PM
apnews.com logoThe Law Offices of Frank R. Cruz Announces Investigation of Spero Therapeutics, Inc. (SPRO) on Behalf of Investors
apnews.com - June 3 at 3:31 AM
apnews.com logoINVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Spero Therapeutics, Inc. (SPRO) on Behalf of Investors
apnews.com - June 2 at 10:30 PM
Get Spero Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SPRO and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:SPRO) was last updated on 10/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.